Choate, Hall & Stewart LLP Podcast

Utilizing ESG as Criteria in Investment Analysis

14 min · 23 de oct de 2023
Portada del episodio Utilizing ESG as Criteria in Investment Analysis

Descripción

In this episode of the Family Office Services Podcast Series [https://www.choate.com/insights/utilizing-esg-as-criteria-in-investment-analysis.html], Choate Investment Advisors’ [https://www.choateia.com/] Erin Kerr [https://www.choateia.com/team.html#erin-e-kerr-cfa] and Alison Svizzero [https://www.choateia.com/team.html#alison-svizzero] discuss how environmental, social, and governance (ESG) criteria are used by investors in evaluating companies, in addition to traditional fundamental analysis, to determine long-term performance. ESG has increased as an area of interest for investors over the past decade. Erin, who is a ChoateIA Chief Compliance Officer and the Chief Investment Officer, and Alison, a Portfolio Manager and the Head of Private Equity Investing, provide a comprehensive overview and debunk myths related to utilizing ESG as investment criteria.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Choate, Hall & Stewart LLP Podcast!

Empezar

2 meses por 1 €

Después 4,99 € / mes · Cancela cuando quieras.

  • Podcasts exclusivos
  • 20 horas de audiolibros / mes
  • Podcast gratuitos

Todos los episodios

28 episodios

Portada del episodio Salix v. Norwich Patent Infringement Opinion and the Implications of a Post-Trial ANDA Amendment and Section 8 Carveout

Salix v. Norwich Patent Infringement Opinion and the Implications of a Post-Trial ANDA Amendment and Section 8 Carveout

In this episode of our Life Sciences Insights podcast series, Sophie Wang and Madison Garrett discuss the Federal Circuit’s recent opinion in a patent infringement case between Salix Pharmaceuticals and Norwich Pharmaceuticals. The opinion arises out of Hatch-Waxman litigation concerning Norwich’s Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of Salix’s drug, rifaximin, marketed under the brand name Xifaxan®. Sophie and Madison discuss two main components of the opinion: (1) the use of a clinical trial protocol as prior art to render obvious a claim directed to a method of treatment with particular dosages, and whether that supports a reasonable expectation of success, and (2) the implications of a post-trial ANDA amendment with a section 8 carveout (a.k.a. skinny label) on an injunction order from the litigated case.

1 de may de 202413 min
Portada del episodio Utilizing ESG as Criteria in Investment Analysis

Utilizing ESG as Criteria in Investment Analysis

In this episode of the Family Office Services Podcast Series [https://www.choate.com/insights/utilizing-esg-as-criteria-in-investment-analysis.html], Choate Investment Advisors’ [https://www.choateia.com/] Erin Kerr [https://www.choateia.com/team.html#erin-e-kerr-cfa] and Alison Svizzero [https://www.choateia.com/team.html#alison-svizzero] discuss how environmental, social, and governance (ESG) criteria are used by investors in evaluating companies, in addition to traditional fundamental analysis, to determine long-term performance. ESG has increased as an area of interest for investors over the past decade. Erin, who is a ChoateIA Chief Compliance Officer and the Chief Investment Officer, and Alison, a Portfolio Manager and the Head of Private Equity Investing, provide a comprehensive overview and debunk myths related to utilizing ESG as investment criteria.

23 de oct de 202314 min